#Other countries : The European Commission authorized on Wednesday the marketing of the Ebola vaccine from the Janssen laboratory, a Johnson & Johnson subsidiary, the second treatment of this type to receive the green light from the EU.
The decision was quick, in a month, against two in normal times, the institution said in a statement. “This is the second vaccine against the Ebola virus that the Commission has authorized in less than a year and confirmed once moreover, the EU remains at the forefront of the global effort to save lives from this virus, “said Health Commissioner Stella Kyriakides.
READ ALSO: Ebola: Spanish researchers want to reach a universal vaccine
“We know very well, thanks to the coronavirus crisis, that viruses do not respect borders – protecting the health of others is protecting the health of all,” she said. In November, the Commission authorized the marketing of the vaccine from the American laboratory Merck under the trade name Ervebo on the EU market.
At the end of June, the Democratic Republic of the Congo offered itself a brief respite on the health front by proclaiming the end of its tenth Ebola epidemic, declared on August 1, 2018 in the east of the country, which on Congolese soil killed 2,287 people for 3,470 cases.
READ ALSO: Ebola: Gabon has an ultra-secure laboratory against the virus
For the first time, vaccination has been widely used on more than 320,000 people, with the two vaccines not yet approved by Merck and Johnson & Johnson. However, the virus remains active and a new outbreak was declared in May in the west of the country.- .
